Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 3Thoracic 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Hereditary Breast and Ovarian Cancer Syndrome 1

Interventions

Paclitaxel 140pembrolizumab 119Carboplatin 104Bevacizumab 90Cisplatin 67Specimen Handling 62Magnetic Resonance Spectroscopy 51olaparib 50Gemcitabine 39Nivolumab 36Biopsy 36liposomal doxorubicin 32Taxes 31Cyclophosphamide 31Blood Specimen Collection 29niraparib 27lenvatinib 26Letrozole 26Doxorubicin 26Topotecan 25Drug Therapy 25Immunoglobulin G 22fludarabine 21atezolizumab 21Radiotherapy 21Brachytherapy 21Disulfides 20durvalumab 19Surveys and Questionnaires 19dostarlimab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Genotype × Gynecologic × 1 year × Clear all
NCT06534424 2025-06-27

Clinical Impact of Enhanced Risk Assessments in Women With a BRCA1/2 Mutation, CARE Study

Ohio State University Comprehensive Cancer Center

Phase NA Completed
152 enrolled
BreastGynecologic

Hereditary Breast and Ovarian Cancer Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡